ProCE Banner Activity

AUGMENT-101 and SAVE: Revumenib-Based Therapy in R/R Acute Leukemias

Conference Coverage
Slideset

In this updated analysis of the phase II part of the AUGMENT-101 trial, revumenib was associated with high rates of response, MRD negativity, and the ability to proceed to HSCT in heavily pretreated patients with KMT2A-rearranged R/R acute leukemias. Further, in an analysis of the phase I/II SAVE trial, the investigational combination of revumenib, venetoclax, and oral decitabine/cedazuridine was associated with high efficacy and tolerability in adults and children with R/R AML susceptible to menin inhibition.

Released: December 16, 2024

Expiration: December 15, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation